drugset
drugset / Trial / NCT05600777

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777 ↗

Phase 3 Active not recruiting 997 enrolled Bellus Health Inc. - a GSK company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Timeline

Start
2022-12-05
Primary completion
2026-06-10
Completion
2027-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule 25 mg Oral
Subject Camlipixant Small molecule 50 mg Oral

Indications

respiratory system disorder